Selective estrogen receptor downregulators (SERDs)

Fulvestrant      

Select            
Trial Studied trt Control trt patientstagsROB Trial result

advanced breast cancer (metastatic)

fulvestrant
GEICAM/2006-10    NCTfulvestrant + anastrozoleanastrozole HER-2 negative HR positive postmenopausal Risk of bias -
FACT (Bergh), 2012      NCTfulvestrant + anastrozoleanastrozole first line of endocrine therapy HR positive postmenopausal negative
Mehta(SWOG-S0226), 2012      NCTfulvestrant + anastrozoleanastrozole HR positive suggesting
Xu et al., 2011      NCTfulvestrant 250mganastrozole HR positive postmenopausal Low risk of bias -
0021 (Osborne), 2002      NCTfulvestrant 250mganastrozole postmenopausal Low risk of bias negative
0020 (Howell), 2002     fulvestrant 250mganastrozoleRisk of bias negative
FIRST (Robertson), 2010    NCTfulvestrant 500mganastrozole first line of endocrine therapy postmenopausal suggesting
9238UK/0005 (fluvestrant alone)    NCTfluvestrant 250mgexemestane postmenopausal previously treated with endocrine therapy Low risk of bias -
SoFEa (Johnston) fluvestrant alone, 2012      NCTfluvestrant 250mgexemestane postmenopausal previously treated with endocrine therapy -
9238UK/0005 (combination)    NCTfulvestrant + anastrozoleexemestane postmenopausal previously treated with endocrine therapy Low risk of bias -
SoFEa (Johnston) combination, 2012      NCTfulvestrant + anastrozoleexemestane HR positive postmenopausal previously treated with endocrine therapy negative
EFECT (Chia)    NCTfulvestrant 250mgexemestane HR positive postmenopausal Low risk of bias negative
D6997L00021    NCTfulvestrant 500mgfulvestrant 250mg HR positive previously treated with endocrine therapy Low risk of bias -
CONFIRM (Di Leo), 2010      NCTfulvestrant 500mgfulvestrant 250mg HR positive previously treated with endocrine therapy Low risk of bias -
FINDER 1 (Ohno), 2010     fulvestrant 500mgfulvestrant 250mg postmenopausal -
FINDER 2, 2010      NCTfulvestrant 500mgfulvestrant 250mg postmenopausal previously treated with endocrine therapy Exploratory -
9238IL/0025    NCTfulvestrant 250mgtamoxifen first line of endocrine therapy Low risk of bias -
0025 (Howell), 2004     fulvestrant 250mgtamoxifen previously treated with endocrine therapy Low risk of bias negative